Brief: Ryvu Therapeutics Says Total Non-Cash Expense From Incentive Programme Will Amount To PLN 51-62 Mln Spread Over 2021-2024
13/05/2021 16:40
May 13 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* TOTAL NON-CASH EXPENSE FROM INCENTIVE PROGRAMME WILL
AMOUNT TO
PLN 51-62 MILLION SPREAD OVER 2021-2024
* COST OF PROGRAM WILL BE INCLUDED IN COMPANY'S QUARTERLY
FINANCIAL STATEMENTS
Source text for Eikon: ID:nEM2nQbjba
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project